Opthea Limited Sponsored ADR (OPT) Price & Analysis

Compare

197 Followers

OPT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.03 - $6.30

Previous CloseN/A

Volume12.29K

Average Volume (3M)0.00

Market Cap

$490.60M

Enterprise Value$689.39M

Total Cash (Recent Filing)$172.47M

Total Debt (Recent Filing)$141.65M

Price to Earnings (P/E)―

Beta2.20

Next Earnings

Feb 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.20

Shares Outstanding153,910,920

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.41

Enterprise Value/Revenue3.78K

Enterprise Value/Gross Profit-5.81K

Enterprise Value/Ebitda-2.41

Forecast

1Y Price Target

$1.00

Price Target Upside-68.75% Downside

Rating ConsensusHold

Number of Analyst Covering0

Bulls Say, Bears Say

Bulls Say

Bears Say

Clinical TrialsOpthea's Phase 3 COAST trial of sozinibercept in combination with Eylea for wet age-related macular degeneration failed to meet its primary endpoint, which is disappointing.

Financial SolvencyThe company could be required to pay four multiples of the amounts paid to the company upon termination of the DFA agreement, which would have a material impact on the solvency of the company.

Stock DowngradeGiven the negative readout, the stock is downgraded to MP and the price target moves from $12 to $1.

Opthea Limited Sponsored ADR News

Opthea Limited Reports Improved Financial Results Amid R&D Challenges

Opthea Limited Sponsored ADR ( ($OPT) ) just unveiled an update. Opthea Limited reported its financial results for...

21d ago

OPT

Opthea terminates COAST trial, announces ShORe trial misses endpoint

Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline...

6M ago

OPT

Opthea downgraded to Perform from Outperform at Oppenheimer

Oppenheimer downgraded Opthea (OPT) to Perform from Outperform. Published first on TheFly – the ultimate source for real-time,...

6M ago

OPT

Opthea downgraded to Market Perform from Outperform at Leerink

Leerink analyst Marc Goodman downgraded Opthea (OPT) to Market Perform from Outperform. Published first on TheFly – the...

6M ago

OPT

Opthea cut to Market Perform at Leerink on failed sozinibercept trial

Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12....

6M ago

OPT

Opthea double downgraded to Underperform from Buy at Jefferies

Jefferies double downgraded Opthea (OPT) to Underperform from Buy with a price target of $1, down from $8,...

6M ago

OPT

Opthea downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield downgraded Opthea (OPT) to Neutral from Buy with a price target of $2,...

6M ago

OPT

CoreWeave initiated, Carvana upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

6M ago

AJG

AON

Hold Rating Issued for Opthea Limited Amid Uncertainty Following Phase 3 Trial Failure

In a report released today, Matthew Caufield from H.C. Wainwright maintained a Hold rating on Opthea Limited Sponsored...

6M ago

OPT

Opthea Limited: Hold Rating Amid Phase 3 Trial Failure and Financial Uncertainty

In a report released yesterday, Marc Goodman from Leerink Partners downgraded Opthea Limited Sponsored ADR (OPT – Research...

6M ago

OPT

Opthea’s COAST Phase 3 Trial Fails to Meet Primary Endpoint, Raising Financial Concerns

Opthea Limited Sponsored ADR ( ($OPT) ) has shared an update. Opthea Limited announced that its COAST Phase...

6M ago

OPT

Opthea COAST trial misses primary endpoint, enters talks with DFA Investors

Opthea (OPT) announced results from its global Phase 3 clinical trial COAST in patients with wet AMD. The...

6M ago

OPT

Opthea Ltd (ADR) trading halted, news pending

10:07 EDT Opthea (OPT) Ltd (ADR) trading halted, news pending Published first on TheFly – the ultimate source...

6M ago

OPT

Opthea Limited: Promising Clinical Trials and Strong Financial Position Support Buy Rating with $13 Target

JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on OPT stock, giving a Buy rating on February...

7M ago

OPT

OPT FAQ

What was Opthea Limited Sponsored ADR’s price range in the past 12 months?

Opthea Limited Sponsored ADR lowest stock price was $3.03 and its highest was $6.30 in the past 12 months.

What is Opthea Limited Sponsored ADR’s market cap?

Opthea Limited Sponsored ADR’s market cap is $490.60M.

When is Opthea Limited Sponsored ADR’s upcoming earnings report date?

Opthea Limited Sponsored ADR’s upcoming earnings report date is Feb 26, 2026 which is in 160 days.

How were Opthea Limited Sponsored ADR’s earnings last quarter?

Opthea Limited Sponsored ADR released its earnings results on Aug 29, 2025. The company reported -$0.201 earnings per share for the quarter, missing the consensus estimate of -$0.07 by -$0.131.

Is Opthea Limited Sponsored ADR overvalued?

According to Wall Street analysts Opthea Limited Sponsored ADR’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Opthea Limited Sponsored ADR pay dividends?

Opthea Limited Sponsored ADR does not currently pay dividends.

What is Opthea Limited Sponsored ADR’s EPS estimate?

Opthea Limited Sponsored ADR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Opthea Limited Sponsored ADR have?

Opthea Limited Sponsored ADR has 153,910,920 shares outstanding.

What happened to Opthea Limited Sponsored ADR’s price movement after its last earnings report?

Opthea Limited Sponsored ADR reported an EPS of -$0.201 in its last earnings report, missing expectations of -$0.07. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Opthea Limited Sponsored ADR?

Currently, no hedge funds are holding shares in OPT

Opthea Limited Sponsored ADR Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-69.91%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Opthea Limited Sponsored ADR

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.